Cambridge Cognition signs two PTSD trial agreements

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced two agreements in a new therapeutic area for the Company, post-traumatic stress disorder.  Most recently, a research agreement was entered into with the with the United States Department of Defense, following on from a contract secured earlier this year with a top 10 pharmaceutical company.  Approximately 20 PTSD treatment trials run every year1, demonstrating the potential for further sales in this therapeutic area. 

PTSD affects around 15 million adults a year2 and up to 31% of veterans, many of whom do not experience relief from their symptoms with existing medications. It has been suggested that the symptoms of PTSD could directly lead to deficits in executive functioning, including re-experiencing memories, problems with concentration, and hyperarousal interrupting working memory performance3

Only two pharmacological treatments for PTSD have received FDA-approval. One reason for this could be that drug response is highly variable between affected individuals, making it difficult to develop effective treatments. In efforts to address the therapeutic need, the United States Department of Defense is developing a precision medicine approach to PTSD. Cambridge Cognition has been selected as a cognitive assessment provider for the project because CANTABTM offers accurate measurement of the potentially distinct pathophysiological processes involved in PTSD.

Pharmaceutical companies are also investigating the potential for new drug classes for PTSD.  Recently, a top 10 pharmaceutical company has contracted with Cambridge Cognition to be their cognitive assessment partner for an upcoming PTSD treatment trial. In delivering the contract, Cambridge Cognition will provide its proprietary cognitive assessment tool, CANTABTM, as an exploratory endpoint.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“Cognitive impairment is increasingly recognised as a major component of PTSD.  At Cambridge Cognition, we are pleased to be providing the company’s expertise to monitor cognitive symptoms with a view to improving outcomes for those suffering from the after-effects of major trauma.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions of Clinpal

Cambridge Cognition Holdings

Cambridge Cognition investor webinar on 3 May 2023

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, will be announcing the Company’s preliminary financial results for the year ended 31 December 2022 on Wednesday 3 May 2023 and is pleased

Cambridge Cognition Holdings

Cambridge Cognition Holdings confirm date for year end results

Cambridge Cognition Holdings Plc (LON: COG), which develops and markets digital solutions to assess brain health, has confirmed that it will announce the Company’s preliminary financial results for the year ended 31 December 2022, on Wednesday 3 May 2023.

Cambridge Cognition Holdings

Cambridge Cognition wins two contracts worth over £2.1 million

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won two sizeable contracts, together worth over £2.1 million, to provide the Company’s CANTAB® cognitive assessments and electronic

Cambridge Cognition Holdings

Cambridge Cognition 25% growth in revenues to £12.6 million

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a trading update for the year ended 31 December 2022. Unaudited highlights for the year ended 31 December 2022 ·         Revenue ahead of

Cambridge Cognition Holdings

Cambridge Cognition acquires Winterlight Labs Inc

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the acquisition of Winterlight Labs Inc, a leader in monitoring cognitive impairment through free-speech analysis.  The total consideration for the Acquisition is

Cambridge Cognition Holdings

Cambridge Cognition plc investor live webinar today

The interim results for the six months ended 30 June 2022 were released earlier today on 20 September 2022. The Company will conduct a live presentation and Q&A session for investors later today at 5:30 pm BST. The presentation

Cambridge Cognition Holdings

Cambridge Cognition growth in revenue of 31%

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced its unaudited interim results for the six months ended 30 June 2022. The Company followed its strong performance in 2021 with a 31%

Cambridge Cognition Holdings

Cambridge Cognition partnering with the University of Oxford

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it will be collaborating with the University of Oxford by providing cognitive assessments for the Impact of Semaglutide in Amyloid

Cambridge Cognition Holdings

Cambridge Cognition directors buy shares in company

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, announced today that it was informed on the 21st July 2022 of the following purchases of the Company’s ordinary shares by Directors and PDMRs of the

No more posts to show